Comparing SG&A Expenses: ACADIA Pharmaceuticals Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Pharmaceuticals

In the competitive landscape of pharmaceuticals, understanding financial trends is crucial. Over the past decade, ACADIA Pharmaceuticals Inc. and Amphastar Pharmaceuticals, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses.

ACADIA Pharmaceuticals Inc.

From 2014 to 2023, ACADIA's SG&A expenses surged by over 1,100%, peaking in 2023. This growth reflects their aggressive expansion and investment in marketing and administrative capabilities. Notably, their expenses in 2023 were nearly five times higher than in 2014, indicating a strategic focus on scaling operations.

Amphastar Pharmaceuticals, Inc.

Conversely, Amphastar's SG&A expenses grew by approximately 100% over the same period. While their growth is more modest, it suggests a steady and controlled approach to managing operational costs. Their expenses in 2023 were about twice those in 2014, highlighting a consistent yet cautious expansion strategy.
These insights reveal contrasting strategies in managing operational costs, offering a window into each company's priorities and market positioning.